A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies
Todd Rosenblat(Columbia University Irving Medical Center), Mark G. Frattini(Presbyterian Hospital), Mark Heaney(Immunovaccine (Canada)), Hakim Djaballah(High Throughput Biology (United States)), Jacquelyn Gonzales(Columbia University Irving Medical Center), Joseph G. Jurcic(Memorial Sloan Kettering Cancer Center), Leah J. Hogdal(Harvard University), Joseph M. Scandura(Cornell University), Anthony Letai(Dana-Farber Cancer Institute), Kevin Zikaras(Columbia University Irving Medical Center), Martin Santos(Columbia University Irving Medical Center), Azra Raza(University of Illinois Chicago), Jennifer L. Crombie(Dana-Farber Cancer Institute), Rong Zhang(Columbia University Irving Medical Center), David Shum(Memorial Sloan Kettering Cancer Center), Ruth Santos(Columbia University Irving Medical Center), J. Gregory Mears(Columbia University Irving Medical Center), Diana Carrillo(Columbia University Irving Medical Center), Glorymar Ibanezs(Memorial Sloan Kettering Cancer Center)
Cited by 1
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k